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Abstract: Crohn's disease (CD) is an inflammatory, chronic and progressive disease that affects the digestive 
tract. Despite optimized drug therapy, the risk of multiple surgical interventions over the years is high, leading the 
patient to develop short bowel syndrome (SBS). Thus, adequate management in the postoperative period directly 
interferes with the long-term prognosis. Initially, most of these patients, due to hydro electrolytic disorders and 
absorptive incapacity inherent in SBS, will need parenteral nutritional support. According to the patient's residual 
digestive profile and according to nutritional management (oral, enteral, and/or parenteral), the intestine will 
evolve in its adaptive capacity. During this period, control agents are used for motility and intestinal secretion and, 
if necessary, GLP-2 agonists (intestinotrophic). In cases refractory to these treatments, we can still indicate 
surgical procedures to control motility, increasing intestinal length, and, finally, transplantation. CD is recurrent, 
and patients with SBS need a multidisciplinary approach with continuous monitoring to provide better intestinal 
rehabilitation and consequent quality of life. 
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Introduction 
 Crohn's disease (CD) is a chronic and 
progressive inflammatory disease, characterized by 
transmural involvement of the digestive tract. This is 
the reason for the frequent appearance of strictures, 
abscesses, and intestinal fistulas [1]. Despite advances 
in drug treatment, more than half of patients with CD 
will undergo intestinal resections in the next 10 years 
after diagnosis of the disease. Of these, one-third will 
still need a second intestinal resection in 5 years after 
the first procedure [2]. 
 Since most patients develop the disease 
between adolescence and early adulthood, frequent 
resections may develop short bowel syndrome (SBS) 
and/or intestinal failure (IF). The risk factors for such 
situations are young age at diagnosis and first surgery, 
a disease with stenosis, family history of inflammatory 
bowel disease, smoking, and postoperative 
complications [3]. 
 For these reasons, the CD is one of the most 
common causes of IF with the need for home 
parenteral nutrition (HPN). In the UK alone, it accounts 
for 25% of all causes of IF, while in Japan, a study 
revealed an incidence of IF of 3.6; 6.1, and 8.5% in 
10, 15, and 20 years of illness, respectively. This 
situation is extremely morbid, with an important 
impact on quality of life [3]. 
 In the last decade, the frequent use of 
biological agents in the treatment of CD has brought 
promising results, expecting a reduction in long-term 
surgical procedures with their use [4]. It still lacks data 
to support this hypothesis [5]. However, a population-
based cohort study found a 2.2-fold lower risk for 
surgical intervention in the era of use of biological 
agents when compared to the era without the use of 
these drugs [4, 5]. 
 Therefore, the present study aimed to discuss 
the epidemiological and pathological aspects of 
intestinal failure with short bowel syndrome in CD 





 The rules of the Systematic Review-PRISMA 
Platform (Transparent reporting of systematic reviews 
REVIEW ARTICLE 
MedNEXT J Med Health Sci 2(2) (2021) 77-86 
 Vol 2 Iss 2 Year 2021               Hayslan Theobaldo Boemer et al.,/2021          
 
Page 78 of 86 
and meta-analysis-HTTP: //www.prisma-
statement.org/) were followed [6]. 
 
Data sources and research strategy 
 The search strategies for this systematic 
review were based on the keywords (MeSH Terms): 
“Intestinal failure. Short bowel syndrome. Crohn's 
disease. Nutritional support”. The research was carried 
out in October 2018 to May 2019 and developed based 
on SCOPUS, PUBMED, and SCIENCE DIRECT, including 
the National Institutes of Health RePORTER Grant 
database and clinical trial records. Also, a combination 
of the keywords with the booleans "OR", AND and the 
operator "NOT" were used to target the scientific 
articles of interest. The title and abstracts were 
examined under all conditions. 
 
Study Quality and Bias Risk 
 The quality of the studies was based on the  
 
GRADE instrument [7] and the risk of bias was 
analyzed according to the Cochrane instrument [8]. 
Two independent reviewers carried out research and 
study selection. Data extraction was performed by 
reviewer one and fully reviewed by reviewer two. A 
third investigator decided on some conflicting points 
and made the final decision to choose the articles. 
Only studies reported in English have been evaluated. 
 
Results and Discussion 
 A total of 155 articles were found involving the 
Intestinal Failure and Short Bowel Syndrome in Crohn’s 
Disease. Initially, duplication of articles was excluded. 
After this process, the abstracts were evaluated and a 
new exclusion was performed, removing articles that 
did not include the theme of this article. A total of 65 
articles were evaluated in full and 20 were included in 
the systematic review (Figure 1). 
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After this process, the abstracts were evaluated and a 
new exclusion was performed, removing articles that 
did not include the theme of this article. A total of 65 
articles were evaluated in full and 20 were 
 Considering the Cochrane tool for risk of bias, 
the overall assessment resulted in 1 study with a high 
risk of bias and 2 studies with uncertain risk. The 
domains that presented the highest risk of bias were 
related to the number of participants in each study 
addressed. Also, there was an absence of the source 
of funding in 2 studies and 3 studies did not disclose 
information about the conflict-of-interest statement. 
 After a thorough analysis of these selected 
studies, it was found that Crohn's disease has been 
increasing its occurrence worldwide in recent decades. 
This growth stands out mainly in developed countries 
and urban areas. Unlike other diseases, there is no 
differentiation between sexes in its occurrence [1]. 
 The onset of CD occurs with higher rates 
between the second and fourth decade of life, with a 
small peak between 50 and 60 years [1]. It can reach 
frequencies as high as an incidence of 20.2 to 29.3 per 
100,000 inhabitants/year, as is the case in Canada and 
Australia, and a prevalence of 322 (Europe) to 214 
(United States) cases per 100,000 inhabitants [1]. 
Latin America also follows this growth, with the most 
expressive rates in Brazil, which revealed an increase 
in the incidence of CD from 0.08 (the year 1988) to 
5.48/100,000 inhabitants/year in 2015 [9]. 
 Although the proportion of surgical treatment 
in CD has been decreasing in recent years, the 
increase in its incidence continues to make it common 
to find patients with surgical complications. CD is 
among the main causes of intestinal failure requiring 
HPN. North American data from the 90's estimate that 
11% of patients using HPN are caused by 
complications related to CD (second major cause) [5]. 
Although the prevalence of HPN has decreased in the 
United States (EU), in 2013 there was still an average 
of 79 cases million people and an increase of 2.5 times 
the use of household EN (1385/million inhabitants) 
when compared to the 1990s [10-13]. 
 Among the 1115 adults who underwent bowel 
transplantation in the US between 1990 and 2014, 
short bowel syndrome was the most common 
indication (75%) for this procedure, which includes CD 





 CD has multiple subtypes, which contribute to 
its observed clinical heterogeneity. This concept was 
reinforced by the recognition of the complexity of 
genetic, microbial, immune, and environmental factors 
that affect the risk of the disease, although the 
etiology is not fully understood, the CD is still classified 
as an inflammatory bowel disease with autoimmune 
pathophysiology. 
 Autoantibodies are activated against the 
function of the intestinal epithelial barrier and 
circulating antibodies are present in front of a variety 
of autoantigens, including lymphocyte antigens. The 
tumor necrosis factor (TNF) has a central role and the 
specific inhibition of this pleiotropic cytokine by 
biological anti-TNF agents has been a great advance in 
the treatment of CD [12]. 
 An association has been demonstrated 
between CD and the NOD2 mutation (“nucleotide 
oligomeric domain 2”): the defect is responsible for an 
inadequate immune response, damaging function of 
the mucous barrier, and microbial dysbiosis. Thus, the 
hypothesis was raised that the deficiency of NOD2 
leads to a microbial dysbiosis associated with the 
specific and transmissible mucosa, regardless of the 
defect of the mucosal barrier [12]. 
 Since the risk of surgical intervention in CD 
increases progressively with the years of illness, the 
possibility of the appearance of SBS arises, followed by 
IF. The latter is characterized by temporary or 
permanent intestinal malabsorption. The most recent 
guidelines define IF as “a reduction in the intestinal 
function below the minimum required for the 
absorption of macronutrients and/or water and 
electrolytes so that intravenous supplementation is 
necessary to maintain health and/or growth” [13].  
 It is most often caused by short bowel 
syndrome (SBS), which occurs after the removal of 
half or more of the small intestine, therefore, SBS is 
the cause of 74% of patients in home parenteral 
nutrition and of this total, 29% are consequent to CD 
[15,16]. The risk for developing SBS after surgery on 
CD is closely related to the length of the remaining 
small intestine, preserving at least 200 cm of the small 
intestine can reduce the risk of SBS [3]. 
 In this context, there are 3 recognized IF 
categories. The first is self-limited or “Type 1”, which 
occurs more often after abdominal surgery and 
resolves with nutritional or liquid support in the short 
term. "Type 2" IF is associated with septic, metabolic 
MedNEXT J Med Health Sci 2(2) (2021) 77-86 
 Vol 2 Iss 2 Year 2021               Hayslan Theobaldo Boemer et al.,/2021          
 
Page 80 of 86 
or nutritional complications of difficult surgical 
procedures in patients with CD or patients with 
mesenteric vascular disease [3]. Despite advances in 
intensive care, antibiotic therapy, and nutritional and 
metabolic support, IF Type 2 is still associated with 
considerable morbidity and mortality. Intensive care is 
crucial to reduce the likelihood of these patients 
developing “Type 3” IF, which is characterized by the 
need for long-term parenteral nutrition [3]. 
 The most common reason for the development 
of type 3 IF in patients with CD is the inadvertent 
intestinal injury resulting from the management of 
type 2 IF that has developed as a complication of 
surgical resection. Preventing type 3 IF is, therefore, a 
fundamental objective for the surgeon who treats 
patients with type 2 IF. Table 1 summarizes the types 
of intestinal failure, their description, examples, and 
management goals [17]. 
 
Table 1. Types of Intestinal Failure 
Types Description Time Examples Management goals 
Type I IF 
I Acute 
Acute Condition. Others organic 
dysfunctions frequently present. 
Self-limited course when the others 
organic dysfunctions arecorrected 
Days 
Postoperative paralytic ileus 
or bankruptcy syndrome 
multiple organs. 






Acute Acute condition prolonged. 
Continuity of instability metabolic 
Weeks to 
months Abdominal sepsis 
recurring with or without 
fistula. Phase 
acute short intestine. 
Maintain clinical 
stability without sepsis 
or another organ 
dysfunction. IF 
resolution or evolution 




Chronic organ failure without organic 
dysfunction acute. Condition of 
clinical stability. 
Months 






Nutritional and healing 
optimization of wounds. 
Restoration of intestinal 
integrity when possible. 












 Therefore, the prognosis of SBS that will 
require HPN is directly related to the combination of 
the patient's digestive remnant. Table 2 shows the 
thresholds for HPN dependence [2, 3, 17]. The 
presence of intestinal ileus is also a prognosis in the 
use of HPN. Resections greater than 100 cm of the 
ileum are related to insufficient absorption of bile salt, 
causing damage to the enterohepatic bile recirculation 
and the consequent impact on fat absorption. It also 
participates in enteric hormonal feedback mechanisms 
that delay gastric emptying, called “ileal brake” and 
regulate the migratory motor complex. 
 The absence of the “ileal brake” leads to faster 
intestinal transit and a reduction in the contact time for 
nutrient absorption. The presence of the ileocecal 
valve helps to reduce this flow, in addition to 
preventing the migration of bacteria from the colon, 
causing bacterial overgrowth. Also, hypersecretion of 
gastric acid and the "clearance" of gastric acid content 
in the duodenum impair the activity of pancreatic 
enzymes, subsequently contributing to the 
malabsorption of fat [2]. 
 The colon's importance in preserving 
nutritional autonomy is related to its primary role in 
the absorption of fluids, electrolytes, and fatty acids. 
Normally, between 1 and 2 L of feces can enter the 
cecum every day, and the colon dramatically reduces 
up to 90% of the water content to 100 to 200 mL of 
feces. Colon bacteria also ferment indigestible 
carbohydrates into short-chain fatty acids, which serve 
Table 2. Predisposing Anatomy and Residual Length for Parenteral Nutrition Dependence* 
Residual Intestinal Anatomy Average length for dependence on 
parenteral nutrition 
Terminal jejunostomy 
< 100-115 cm 
Jejunocolic anastomosis 
< 60-65 cm 
Jejunoileal anastomosis (colon in continuity) 
< 30-35 cm 
*Adapted from reference 2. 
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as a source of calories. Thus, the absence of the colon 
severely impairs fluid absorption and reduces short-
chain fatty acids as a source of calories [2]. 
 
Intestinal Adaptation 
 Intestinal adaptation refers to a process by 
which this organ undergoes several structural and 
functional changes to compensate for the loss of 
intestinal function due to injury or resection. As a 
result, both the colon and the small intestine undergo 
metaplasia and hyperplasia, adapting to changes in the 
intestinal anatomy received [18]. 
 Among the segments of the digestive tract, the 
ileum is more skilled in the ability to perform 
metaplasia of the colonic cells and in the growth of the 
villi to compensate for the absence of the colon. This, 
in turn, has an intermediate potential to develop ileal 
cells, while the jejunum has a weak potential for 
adaptation. These differences partially explain the 
significance of the ileum and the colon in preserving 
nutritional autonomy [2, 18]. 
 In general, the entire process of intestinal 
adaptation usually occurs in 1 to 2 years, starting 
immediately after intestinal resection. It is inversely 
related to the time of use of parenteral nutritional 
support and direction to the use of enteral/oral diet. 
For this reason, the early use of the enteral diet is 
beneficial, even with a trophic infusion rate (15 to 25 
mL/h) [2, 18]. 
 
Complications 
 Morbidity in SBS results mainly from the 
sequelae of malabsorption of fluids and nutrients, 
which occur mainly in the acute postoperative phase of 
intestinal resection; surgical complications, and the 
adverse effects of HPN. Especially in the acute phase, 
fluid resuscitation is essential in all patients with IF, 
and necessary before any nutritional intervention [17]. 
The small intestine usually absorbs 80% of the fluids 
received, while the colon 18%. However, the colon has 
the possibility of increasing its absorption capacity. 
Since fluid loss (diarrhea) is inversely proportional to 
the size of the remaining small intestine, the presence 
of the colon plays an important role in the water 
management of these patients in the postoperative 
period [14]. 
 Thus, patients with terminal jejunostomy or 
proximal ileostomy often develop dehydration and 
electrolyte deficiencies (especially magnesium, 
potassium, and sodium). Normal electrolyte values 
must be achieved in all patients with IF, mainly 
because electrolyte disturbances can aggravate 
gastrointestinal dysmotility [19]. The resection of the 
ileum results in proportionally greater malabsorption 
and diarrhea than the loss of the jejunum, due in part 
to the excess of bile salts and unabsorbed fats that 
reach the colon and also because the jejunum is less 
able to adapt [17]. 
 Patients on exclusive HPN are particularly at 
risk for vitamin, mineral, and trace element 
deficiencies if micronutrients are not monitored and 
replenished accordingly. For example, iron is not 
included in the parenteral nutrition (PN) due to 
compatibility problems and generally requires oral or 
parenteral supplementation [2]. 
 Patients with SBS can develop hepatobiliary 
dysfunction for several reasons, including adverse 
effects of PN, nutritional deficiencies, bacterial 
overgrowth, sepsis, or concomitant liver disease, 
especially in patients with inflammatory bowel disease 
[20]. Liver steatosis can run as short as 2 weeks from 
the onset of PN, however, its course is reversible and I 
rarely progressed to cirrhosis. On the contrary, 
intrahepatic cholestasis can occur at a later time (> 3 
weeks from the onset of PN) and is characterized by 
presenting lymphocytic infiltrate leading to cirrhosis 
and liver failure [2]. 
 Deficiency of amino acids such as taurine, 
choline, carnitine, and glutamine, as well as essential 
fatty acids (linoleic and linolenic acid), can also 
contribute to liver damage. In addition to these 
aspects, it is sought to maintain a PN with an infusion 
of dextrose <5 mg/ kg/min as well as a lipid dose <1 
kg/day, and to avoid excess calories [2,17]. 
 The presence of cholelithiasis is another 
complication seen in SBS. This can be explained by 
reduced oral intake and consequent reduction of 
gallbladder contractions, as well as alteration of 
bilirubin metabolism, mucin hypersecretion, and 
cholesterol supersaturation. Clinical conditions are 
more severe when there is resection or ileal disease. 
 Another important complication to be 
highlighted is a bone mineral disease. It can be 
present in 40 to 100% of patients with intestinal failure 
[2] and 50% of patients with CD [21]. In this 
population, the presence of a very low body mass 
index (BMI), use of glucocorticoids, males, previous 
exposure to gastrointestinal surgery, and smoking are 
risk factors for the development of osteopenia and 
MedNEXT J Med Health Sci 2(2) (2021) 77-86 
 Vol 2 Iss 2 Year 2021               Hayslan Theobaldo Boemer et al.,/2021          
 
Page 82 of 86 
osteoporosis [21, 22]. Thus, it is recommended to 
regularly monitor the levels of calcium and vitamin D, 
as well as their replacement when necessary [22]. In 
patients using HPN, bone densitometry is also 
recommended every 2 years [2]. 
 Patients with SBS and the presence of the 
colon are at elevated risk (1.25 times higher) of 
developing nephrolithiasis due to calcium oxalate 
calculations, especially if there is concomitant ileal 
resection. The mechanism involved in the binding of 
calcium to unabsorbed fatty acids, leaving excess 
oxalate anions available for resorption in the colon. 
This in turn also shows an increase in permeability to 
small molecules, such as oxalate, induced by 
unabsorbed bile acids, facilitating the entry of oxalate 
into the bloodstream. A reduction in the bacterial 
degradation of oxalate due to the decrease in 
Oxalobacter formigenes also leads to an increase in its 
absorption. The combination of high serum oxalate 
concentrations, dehydration, acidic urinary pH, 
predisposes the patient to the formation of renal 
oxalate stones [2, 23]. 
 Strategies to reduce the risk of nephrolithiasis 
include ideal hydration, increased calcium intake (or 
supplementation of 1 to 4g/day of calcium carbonate) 
in the diet, adherence to a diet low in oxalate and fat 
[2]. 24-hour oxaluria monitoring can also be used, as 
the risk of nephrolithiasis becomes high when the 
values exceed 25 mg/day. When necessary (presence 
of metabolic acidosis), potassium citrate can be used 
to alkalinize urine [23]. 
 Finally, survival in patients with intestinal 
failure has been estimated at 94% and 80% at 1 and 4 
years, respectively, and the main cause of death in 
these patients is usually sepsis and liver failure [2]. 
 
Nutritional Management 
 Nutrotherapeutic management requires a 
combination of nutritional, medication, and surgical 
support. The goal is to provide adequate intake of 
fluids and nutrients, minimizing complications and 
impact on quality of life. During the initial stages of 
SBS (acute phase), when the patient is unable to 
consume adequate fluids or nutrients orally, PN may 
be necessary. Oral and/or enteral nutrition should be 
started as soon as possible to promote intestinal 
rehabilitation, especially when diarrhea losses are less 
than 2.0-2.5 L/day. As intestinal adaptation (adaptive 
phase) occurs over successive years (1 to 2 years), the 
balance between oral and parenteral nutrition may 
evolve [2, 18]. 
Parenteral Nutrition 
 Among patients with SBS, PN has a 
fundamental performance in the following: 
postoperative, adaptation, and maintenance periods. 
Thus, in the postoperative period (PO), its main 
function is to guarantee all necessary protein, caloric, 
water, and micronutrient inputs. The patient will hardly 
be able to start any type of oral/enteral diet in the first 
7 to 10 days of PO [2]. 
 As the patient progresses with a reduction in 
the diarrheal condition, the adaptation phase is 
characterized by the transition period between PN and 
progression to oral/enteral diet. In some situations, 
there will still be a dependence on PN, despite the 
presence of the oral/enteral diet. At this moment, the 
maintenance and stabilization phase (adaptive phase) 
is outlined. Table 2 describes the anatomical profile of 
the digestive remnant that presents a high probability 
of dependence on household PN [2]. 
 
Enteral Nutrition 
 Whenever possible, the onset of the EN should 
be stimulated with the consequent weaning of the PN. 
The presence of EN through the gastrointestinal tract 
reduces intestinal permeability and atrophy, promoting 
intestinal adaptation. 
 The standard formula to be started is of the 
polymeric type. Semi-elementary formulas should be 
considered when polymeric formulations are not well 
tolerated. Other characteristics in the formula must 
include an osmolarity of 300 mOsm/L with 100 mmol/L 
of sodium [2]. 
 In the adaptation phase, continuous EN can be 
used in small amounts if the intestinal losses are less 
than 2.5 L/d. The use of continuous EN has been 
shown to increase intestinal absorption in the early 
stages of intestinal adaptation. As an alternative, 
nocturnal EN can serve as a complement to a 
suboptimal oral intake (OI). As in the adaptation 
phase, if the patient is unable to maintain an adequate 




 The most important aspect for dietary 
management in patients with SBS is to encourage 
hyperphagia or an OI greater than 1.5-2 times what 
they were used to eating before the development of 
SBS. Relative malabsorption can be overcome to some 
extent with greater intake [16]. The general nutritional 
principles that apply to all patients with SBS include 
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the separation of food and liquids during meals, 
implementation of smaller and more frequent meals, 
and reduced intake of foods with high osmotic 
properties (for example, concentrated sweets). Other 
nutritional interventions can be individualized 
according to the type and length of the patient's 
residual intestinal anatomy (Table 3).  
For patients with continuing colon, the consumption of 
complex carbohydrates can provide additional calories 
by bacterial fermentation in short-chain fatty acids. 
The restriction of fat and oxalate intake, associated 
with good hydration, is important to reduce the risk of 
nephrolithiasis (Table 4). On the other hand, for those 
with terminal ostomy of the small intestine,  
 
the consumption of fewer carbohydrates and more fat 
in the diet can be useful to reduce the ostomy debt. 
Oxalate restriction is not necessary for patients with 
terminal ostomy [2]. 
 
Micronutrients 
 Micronutrient deficiency is common in SBS. 
Therefore, individualized monitoring is recommended 
according to the remaining anatomy of the digestive 
tract. Table 5 indicates the main areas of absorption 
of micronutrients in the digestive system. 
 
Medication management 
 The medication management of SBS in CD 
uses multiple strategies, such as control of 
inflammation, reduction of intestinal transit, a decrease 
of the intestinal secretion, and induction of intestinal 
growth. The discussion about the therapeutic approach 
to the CD itself will not be detailed in this review. 
 The use of a proton pump inhibitor should be 
administered intravenously initially to suppress gastric 
hypersecretion and reduce fluid losses. Patients with 
SBS usually develop hypersecretion of gastric acid 
during the first six months after resection.  
Table 3. Nutrotherapeutic recommendations in patients with SBS in the presence and/or absence of 
colon 
Type of Diet Terminal Ostomy (without colon) Colon intact 
Carbohydrates Limit concentrated sweets. 
Limit concentrated sweets. 
Favor complex carbohydrates. 
Fats Without restriction, unless there is steatorrhea. Limit. 
Oxalate Absence of restriction. Restrict. 
Fiber Limit if diarrhea gets worse. 
Absence of restriction. Favor 
soluble fibers over insoluble 
fibers. 
*Adapted from reference 2. 
Table 4. Oxalate-containing foods 
Food Category Oxalate-Rich Foods 
Miscellaneous foods Almonds, cashews, peanuts, peanut butter, nuts, tofu, soy. 
Starches Bran, oats, wheat germ, whole grain bread. 
Fruit Apricot, Gooseberry, Fig, Plum, Rhubarb. 
Vegetable Green beans, beets, chard, escarole, eggplant, chives, cabbage, leeks, 
mustard, okra, turnip, spinach, pumpkin, sweet potatoes, parsley, tomatoes, 
watercress. 
Desserts Chocolate 
Drinks Beer, chocolate, colas, tea, instant coffee. 
Spice Black olives, sesame. 
*Adapted from reference 2. 
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 This may be associated not only with peptic 
disease and increased losses of intestinal fluids but 
also with the deactivation of pancreatic enzymes and 
with the reduction of the ideal pH necessary for the 
absorption of fats [10]. 
 Loperamide reduces the speed of transit and 
can assist in the absorption process, as well as control 
intestinal losses. High doses may be necessary (100 
mg/day are not uncommon), always administered in 
divided doses and 30 minutes before meals [10]. 
Anticholinergics are used occasionally, but the common 
side effect of a dry mouth is problematic as it can be 
mistaken for recurrent dehydration. Somatostatin and 
its derivatives are disappointing, as they rarely (<5%) 
help control water balance and can prevent adaptation 
[10]. 
 However, teduglutide, an analog of the natural 
intestinal hormone and trophic factor GLP-2, is 
showing great results. It has a positive effect on the 
small intestine epithelium, and accumulated clinical 
trial data show sustained reductions in the need for 
parenteral nutrition in about 60% of patients (more 
than double that achieved in controls), perhaps with 
10% of patients becoming independent of long-term 
parenteral nutrition after 1 year of treatment. Its price 
can prove to be an important limiting factor when it 
becomes generally prescriptive [10]. 
 
Surgical management 
 The options for SBS can be categorized as 
procedures that change motility, length, and intestinal 
transplantation. In the first situation, we have the 
Small Intestine Reverse Segment Surgery, in which an 
anastomosis of the small segment with an 
antiperistalsis orientation is performed, slowing down 
the digestive transit. In this procedure, a reduction in 
HPN of up to 50% is achieved after 60 months [2]. 
Other similar procedures include colon transposition, 
formation of intestinal valves, and enteroplasty. 
  
 In Bianchi's surgery (intestinal stretching), we 
divide an intestinal segment into two contiguous and 
isoperistaltic parts. Survival after the procedure (16-
year follow-up) was 45%. Among survivors, 77% 
progressed with weaning from HPN [2]. The number of 
bowel transplants has declined dramatically in recent 
years, with the US being the country that most 
performs this procedure (58 cases in 2013). The 
indications are related to long-term complications of  
 HPN catheter-related infections, liver disease 
related to parenteral nutrition, failure of vascular 
access [2, 12].  
The biggest complications of transplantation are 
rejection, infections, and proliferative diseases. CD is 
an additional risk factor for rejection in addition to the 
recurrence of the disease in the graft (7% in 19 
months of follow-up) [2]. 
 Few centers have data related to the survival 
of patients with CD in the postoperative period of 
intestinal transplantation. The UNOS (United Network 
for Organ Sharing) has published a survival rate of 79, 




 Due to its chronic and progressive course, CD 
predisposes the patient to multiple surgical 
interventions, which can lead to SBS. Thus, the proper 
management of the septic condition in the 
postoperative period, associated with nutritional 
support and control of hydro electrolytic disorders 
plays a fundamental role in the prognosis of intestinal 
failure in these patients. Thus, the use of PN with a 
focus on the early onset of EN and the correct use of 
drugs to control motility and intestinal secretion 
contribute to an intestinal adaptation ensuring the 
absence of HPN. In this sense, we can still use 
intestinotrophic agents (eg, teduglutide) when 
Table 5. Micronutrient absorption sites 
Stomach Iodine. 
Duodenum Iron, Zinc, Copper, Selenium, Thiamine Folate. 
Jejunum Vitamin A, D, E, K, Thiamine, Niacin, Folate, B6, C, Iron, Zinc, Chromium. 
Ileus Vitamin B12, A, D, E, K, C, Folate. 
Colon Vitamin K. 
*Adapted from reference 2 
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necessary, as well as surgical procedures and 
ultimately intestinal transplantation. 
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